Table 4.

Correlations among demographic, clinical, psychological variables and SF-36 in gout patients

	PCS		MCS
	r	p	R	p
Gender, male	0.036	0.587	0.044	0.509
Age (years)	−0.051	0.441	0.083	0.214
BMI (kg/m2)	0.077	0.247	0.063	0.344
WHR	−0.094	0.157	−0.044	0.515
Place of residence	−0.160	0.016	−0.110	0.100
Marital status	−0.037	0.578	−0.018	0.788
Education	0.099	0.140	0.065	0.331
Employment status	−0.008	0.907	0.035	0.599
Income/year	0.113	0.090	0.068	0.311
Medical insurance, yes	0.009	0.894	−0.043	0.525
Comorbidities
Hypertension	−0.138	0.038	−0.033	0.621
DM	−0.140	0.036	−0.079	0.238
Hyperlipidemia	−0.005	0.941	0.031	0.643
Cardiovascular disease	−0.194	0.003	−0.182	0.006
Nephropathy	−0.018	0.785	−0.012	0.855
Disease duration (year)	−0.198	0.003	−0.066	0.324
Number of flares/last year	−0.292	<0.001	−0.174	0.009
Stage of gout	−0.066	0.322	−0.060	0.367
Total pain (VAS)	−0.349	<0.001	−0.251	<0.001
Number of tophi	−0.233	<0.001	−0.159	0.017
UA (μmol/L)	−0.083	0.216	−0.100	0.133
Presence of tender joints, yes	−0.175	0.008	−0.243	<0.001
Presence of swollen joints, yes	−0.108	0.105	−0.130	0.051
Urate lowering therapy
Allopurinol	0.087	0.192	0.107	0.107
Febuxostat	0.049	0.467	0.005	0.942
Any anti-inflammatory drugs
Colchicine	−0.157	0.018	−0.159	0.017
NSAID	−0.006	0.925	−0.025	0.712
Corticosteroids	−0.156	0.019	−0.228	0.001
Depression (PHQ-9 ≥ 10 score)	−0.366	<0.001	−0.407	<0.001
Anxiety (GAD-7 ≥ 10 score)	−0.195	<0.001	−0.290	<0.001

SD: standard deviation; IQR: interquartile range; BMI: body mass index; WHR: waist-hip ratio; DM: diabetes; VAS: visual analog scale; sUA: serum uric acid; NSAID: non-steroidal anti-inflammatory drugs, HAQ-DI: health assessment questionnaire-disability index; PHQ-9: patient health questionnaire; GAD-7: generalized anxiety disorder

p values were obtained with Spearman rank correlation analysisanalysis

P numbers of entries with significance are shown in italics